Page 12 - Compass Pathways News Today

Explore the potential of psilocybin therapy for treating mental health conditions like depression, anxiety, and substance use disorders. Learn about its history, how it works, benefits, risks, and more.

By Faith Ashmore, BenzingaTreatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients....

Shares of COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in […]

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to at least two different standard antidepressant treatments.

Could a single tablet help improve the outcome for patients with anorexia? That is the tantalising prospect offered by a study published in August looking at the use of psilocybin, the hallucinogenic component of magic mushrooms.

As the first large pharma operation to make a significant investment in psychedelics, the rewards could be big.

COMPASS Pathways (NASDAQ:CMPS – Get Free Report) and Ramsay Health Care (OTCMKTS:RMSYF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Profitability This table compares COMPASS Pathways and […]

This randomized clinical trial examines the timing of onset of action, durability of benefit, and safety profile of single-dose psilocybin in patients with majo

Objective To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs). Design Umbrella review. Data sources PubMed, PsychInfo, Embase, up to 9 February 2022. Eligibility criteria for selecting studies Systematic reviews with meta-analyses of observational studies and RCTs that have reported on the efficacy and safety of cannabis, cannabinoids, o...

COMPASS Pathways (NASDAQ:CMPS – Free Report) had its price target decreased by Canaccord Genuity Group from $60.00 to $50.00 in a report released on Tuesday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. CMPS has been the subject of a number of other research reports. Cantor Fitzgerald reissued an […]